AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 163.62 million compared to USD 128.72 million a year ago. Basic loss per share from continuing operations was USD 6.08 compared to USD 4.57 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.91 USD | -4.05% | +1.10% | +11.62% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.62% | 681M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023